Literature DB >> 26907653

Central Venous Catheters and Bloodstream Infection During Induction Therapy in Children With Acute Lymphoblastic Leukemia.

Kristin Bergmann1, Henrik Hasle, Peter Asdahl, Mette M Handrup, Peder S Wehner, Steen Rosthøj, Henrik Schrøder.   

Abstract

The purpose of the study was to assess the risk of first-time bloodstream infection (BSI) according to type of central venous catheter (CVC) during induction therapy in children with acute lymphoblastic leukemia (ALL). Patients eligible for our analysis were all newly diagnosed children with ALL treated at 3 pediatric centers in Denmark between 2008 and 2014. A total of 136 patients were followed from initial CVC placement until first BSI, CVC removal, death, or day 28, whichever occurred first. Thirty-nine BSIs were detected, of which 67% were gram-positive infections, and 59% met the criteria for being CVC associated. The 28-day cumulative incidence of BSI was similar in 77 patients with a nontunneled CVC (28%; 95% confidence interval, 19%-40%) and in 59 patients with a tunneled CVC with external lines (TE) (33%; 95% confidence interval, 23%-47%). Subgroup analyses showed that gram-negative blood isolates occurred more frequently in patients with a TE, and that lower incidences of BSI were detected in patients older than 9 years with a TE, and in patients with T-ALL. It is concluded that the type of CVC inserted at diagnosis has no impact upon the risk of BSI in patients with ALL undergoing induction therapy.

Entities:  

Mesh:

Year:  2016        PMID: 26907653     DOI: 10.1097/MPH.0000000000000519

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  1 in total

1.  Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia.

Authors:  Zachary E West; Sharon M Castellino; Caitlin Monroe; Amanda S Thomas; Courtney McCracken; Tamara P Miller
Journal:  Leuk Lymphoma       Date:  2020-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.